Cencora Inc (COR)
Industry Medical Distribution
This stock can be held in an Investment ISA and an Investment Account
Sell
$289.09
Buy
$296.64
$0.30 (+0.10%)
Prices updated at 20 May 2025, 23:57 EDT
| Prices minimum 15 mins delay
Prices in USD
AmerisourceBergen Corp is a pharmaceutical services company. It provides drug distribution and related healthcare services and solutions to pharmacy, physician, and manufacturer customers based in the United States and Canada.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Income statement
Year | 2023 | 2024 |
|---|---|---|
| 262,173m | 293,959m | |
| 8,959m | 9,910m | |
| 2,686m | 3,157m | |
| 1.02 | 1.07 | |
| 1,745m | 1,509m | |
| 3,417m | 3,371m | |
| Sales, General and administrative | 5,310m | 5,661m |
| Interest expenses | 276m | 249m |
| Provision for income taxes | 428m | 485m |
| Operating expenses | 6,274m | 6,753m |
| Income before taxes | 2,161m | 2,004m |
| Net income available to common shareholders | 1,745m | 1,509m |
| 9.28 | 7.11 | |
| Net interest income | -229m | -157m |
| Advertising and promotion | - | - |
| Net investment income, net | - | - |
| Realised capital gains (losses), net | - | - |
| Total benefits, claims and expenses | - | - |
| Earnings per share (diluted) | 9.18 | 7.05 |
| Free cash flow per share | 16.8775 | 14.9663 |
| Book value/share | 2.6171 | 3.3322 |
| Debt equity ratio | 7.9427 | 5.9011 |
Balance sheet
Year | 2023 | 2024 |
|---|---|---|
| Current assets | 42,799m | 47,718m |
| Current liabilities | 48,831m | 54,277m |
| Total capital | 4,668m | 4,458m |
| Total debt | 4,787m | 4,388m |
| Total equity | 522m | 646m |
| Total non current liabilities | - | - |
| Loans | 4,146m | 3,812m |
| Total assets | 62,559m | 67,102m |
| Total liabilities | - | - |
| Cash and cash equivalents | 2,592m | 3,133m |
| Common stock | 201m | 195m |
Cash flow
Year | 2023 | 2024 |
|---|---|---|
| Cash at beginning of period | 3,594m | 2,753m |
| Cash dividends paid | -399m | -416m |
| 3,453m | 2,998m | |
| Investments (gains) losses | -2,602m | -618m |
| 2,753m | 3,298m | |
| Net income | - | - |
| 3,911m | 3,485m | |
| -458m | -487m |
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.
